Structure via PubChem · Public domain (PubChem)
edoxaban
Sign in to saveAlso known as DU-176, DU-176b
Edoxaban, sold under the brand name Lixiana among others, is an anticoagulant medication and a direct factor Xa inhibitor. It is taken by mouth.
Chemical data
- Formula
- C24H30ClN7O4S
- Molecular weight
- 548.1 g/mol
- IUPAC name
- N'-(5-chloro-2-pyridinyl)-N-[(1S,2R,4S)-4-(dimethylcarbamoyl)-2-[(5-methyl-6,7-dihydro-4H-[1,3]thiazolo[5,4-c]pyridine-2-carbonyl)amino]cyclohexyl]oxamide
- SMILES
- CN1CCC2=C(C1)SC(=N2)C(=O)N[C@@H]3C[C@H](CC[C@@H]3NC(=O)C(=O)NC4=NC=C(C=C4)Cl)C(=O)N(C)C
- InChIKey
- HGVDHZBSSITLCT-JLJPHGGASA-N
- XLogP
- 1.4
- Polar surface area
- 165 Ų
- H-bond donors
- 3
- H-bond acceptors
- 8
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 2015
- Admin. routes
- oral
- Indications
- venous thromboembolism, atrial fibrillation, Recurrent thrombophlebitis, hemorrhage
via ChEMBL · EBI
Research
2,849 papers- Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism.The New England journal of medicine · 2018
- Edoxaban in cardiovascular disease management: Review.British journal of clinical pharmacology · 2022
- Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial.European heart journal · 2019
- Edoxaban for 12 Months Versus 3 Months in Patients With Cancer With Isolated Distal Deep Vein Thrombosis (ONCO DVT Study): An Open-Label, Multicenter, Randomized Clinical Trial.Circulation · 2023
- Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial.Lancet (London, England) · 2019
via PubMed
Wikidata facts
- Mass
- 547.176851
- Has use
- medication
Show 9 more facts
- World Health Organisation international non-proprietary name
- 艾多沙班
- chemical formula
- C₂₄H₃₀ClN₇O₄S
- canonical SMILES
- CN1CCC2=C(C1)SC(=N2)C(=O)NC3CC(CCC3NC(=O)C(=O)NC4=NC=C(C=C4)Cl)C(=O)N(C)C
- isomeric SMILES
- CN1CCC2=C(C1)SC(=N2)C(=O)N[C@@H]3C[C@H](CC[C@@H]3NC(=O)C(=O)NC4=NC=C(C=C4)Cl)C(=O)N(C)C
- subject has role
- direct Xa inhibitor
- medical condition treated
- pulmonary embolism
- physically interacts with
- coagulation factor X
- Commons category
- Edoxaban
- defined daily dose
- 60
Sources (10)
via Wikidata · CC0
~6 min read
Encyclopedic overview
9 sectionsContents
- Medical uses
- Contraindications and notes
- Adverse effects
- Overdose
- Mechanism of action
- Pharmacokinetics
- Comparison to other anticoagulants
- Generic availability
- References
Edoxaban, sold under the brand name Lixiana among others, is an anticoagulant medication and a direct factor Xa inhibitor. It is taken by mouth.
Compared with warfarin, it has fewer drug interactions, and does not require regular assessment of blood samples for prothrombin time to assure safe anticoagulant therapy.
Excerpted from Wikipedia’s “edoxaban” article, available under the CC BY-SA 4.0 licence.